First Allied Advisory Services Inc. Sells 1,345 Shares of AstraZeneca plc (AZN)
First Allied Advisory Services Inc. trimmed its holdings in shares of AstraZeneca plc (NYSE:AZN) by 6.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,214 shares of the company’s stock after selling 1,345 shares during the period. First Allied Advisory Services Inc.’s holdings in AstraZeneca were worth $714,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the company. Jennison Associates LLC acquired a new position in shares of AstraZeneca during the second quarter valued at $676,716,000. Fisher Asset Management LLC increased its holdings in shares of AstraZeneca by 4.3% during the second quarter. Fisher Asset Management LLC now owns 13,079,941 shares of the company’s stock valued at $459,237,000 after purchasing an additional 535,782 shares during the period. BlackRock Inc. increased its holdings in shares of AstraZeneca by 3.9% during the first quarter. BlackRock Inc. now owns 6,626,120 shares of the company’s stock valued at $231,715,000 after purchasing an additional 248,598 shares during the period. Schafer Cullen Capital Management Inc. increased its holdings in shares of AstraZeneca by 1.9% during the first quarter. Schafer Cullen Capital Management Inc. now owns 4,463,045 shares of the company’s stock valued at $156,073,000 after purchasing an additional 83,770 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of AstraZeneca by 214.0% during the first quarter. Point72 Asset Management L.P. now owns 2,905,535 shares of the company’s stock valued at $101,607,000 after purchasing an additional 1,980,335 shares during the period. 15.98% of the stock is currently owned by institutional investors.
A number of brokerages have recently commented on AZN. Zacks Investment Research lowered AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, June 29th. Morningstar reissued a “hold” rating on shares of AstraZeneca in a report on Tuesday, June 12th. BMO Capital Markets reissued a “buy” rating and set a $41.00 price target on shares of AstraZeneca in a report on Friday, May 25th. ValuEngine lowered AstraZeneca from a “buy” rating to a “hold” rating in a report on Friday, June 1st. Finally, Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $38.28.
AstraZeneca (NYSE:AZN) last released its earnings results on Thursday, July 26th. The company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.38. The firm had revenue of $5.16 billion for the quarter, compared to analyst estimates of $5.09 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. AstraZeneca’s revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.87 earnings per share. sell-side analysts anticipate that AstraZeneca plc will post 1.68 earnings per share for the current fiscal year.
The company also recently announced a semiannual dividend, which will be paid on Monday, September 10th. Investors of record on Friday, August 10th will be issued a dividend of $0.45 per share. This represents a yield of 2.35%. The ex-dividend date of this dividend is Thursday, August 9th. AstraZeneca’s payout ratio is currently 20.56%.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Hedge Funds Explained
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.